Insider · CIK 0001817226

Beaurang Pierre

Reports to the SEC for 1 company · SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001817226

Forms 4 and 5

Insider transactions

44 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2021-08-10	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+7,500 sh	$1.11	+$8,325	11,830
2021-08-10	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−5,620 sh	$29.74	−$167K	6,210
2021-08-10	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−1,880 sh	$30.21	−$56.8K	4,330
2021-08-10	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−7,500 sh	—	—	6,562
2021-07-12	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+7,500 sh	$1.11	+$8,325	11,830
2021-07-12	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−7,100 sh	$23.88	−$170K	4,730
2021-07-12	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−400 sh	$24.73	−$9,892	4,330
2021-07-12	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−7,500 sh	—	—	14,062
2021-06-10	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+7,500 sh	$1.11	+$8,325	11,830
2021-06-10	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−6,000 sh	$29.15	−$175K	5,830
2021-06-10	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−1,100 sh	$30.01	−$33K	4,730
2021-06-10	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−400 sh	$30.90	−$12.4K	4,330
2021-06-10	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−7,500 sh	—	—	21,562
2021-05-10	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+7,500 sh	$1.11	+$8,325	11,830
2021-05-10	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−4,299 sh	$26.07	−$112K	7,531
2021-05-10	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−2,501 sh	$26.87	−$67.2K	5,030
2021-05-10	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−700 sh	$27.66	−$19.4K	4,330
2021-05-10	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−7,500 sh	—	—	29,062
2021-04-12	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+2,396 sh	$0.84	+$2,012.64	6,726
2021-04-12	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+5,104 sh	$1.11	+$5,665.44	11,830
2021-04-12	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−4,072 sh	$26.83	−$109K	7,758
2021-04-12	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−2,883 sh	$27.67	−$79.8K	4,875
2021-04-12	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−545 sh	$28.65	−$15.6K	4,330
2021-04-12	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−2,396 sh	—	—	0
2021-04-12	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−5,104 sh	—	—	36,562
2021-03-25	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+4,330 sh	$0.84	+$3,637.2	4,330
2021-03-25	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−4,330 sh	—	—	2,396
2021-03-08	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+7,500 sh	$0.84	+$6,300	7,500
2021-03-08	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−2,810 sh	$36.48	−$103K	4,690
2021-03-08	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−4,490 sh	$37.31	−$168K	200
2021-03-08	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−200 sh	$38.34	−$7,668	0
2021-03-08	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−7,500 sh	—	—	6,726
2021-02-18	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+9,107 sh	$0.84	+$7,649.88	9,107
2021-02-18	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+3,797 sh	$7.26	+$27.6K	12,904
2021-02-18	NRIXNurix Therapeutics, Inc.M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	+2,096 sh	$9.57	+$20.1K	15,000
2021-02-18	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−2,647 sh	$34.19	−$90.5K	12,353
2021-02-18	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−4,553 sh	$35.02	−$159K	7,800
2021-02-18	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−6,400 sh	$35.99	−$230K	1,400
2021-02-18	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−1,000 sh	$36.92	−$36.9K	400
2021-02-18	NRIXNurix Therapeutics, Inc.S Sale	Chief Business Officer	SSale	−400 sh	$37.88	−$15.2K	0
2021-02-18	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−9,107 sh	—	—	14,226
2021-02-18	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−3,797 sh	—	—	72,869
2021-02-18	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)M Exercise/Conversion	Chief Business Officer	MExercise/Conversion	−2,096 sh	—	—	14,678
2021-02-11	NRIXNurix Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Chief Business Officer	AAward	+40K sh	—	—	40,000

Recent filings

Accepted (ET)
Aug 114
Beaurang Pierre0001209191-21-050976
SEC(opens sec.gov)
Jul 124
Beaurang Pierre0001209191-21-046362
SEC(opens sec.gov)
Jun 114
Beaurang Pierre0001209191-21-039810
SEC(opens sec.gov)
May 114
Beaurang Pierre0001209191-21-031891
SEC(opens sec.gov)
Apr 134
Beaurang Pierre0001209191-21-026457
SEC(opens sec.gov)

Companies

Nurix Therapeutics, Inc.Chief Business OfficerNRIX

Address

C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205

SAN FRANCISCO, CA, 94158